edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
Company profile
Ticker
EW
Exchange
Website
CEO
Michael Mussallem
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign • RTI Surgical ...
Former names
CVG CONTROLLED INC
SEC CIK
Corporate docs
Subsidiaries
Edwards Lifesciences LLC • Edwards Lifesciences Services GmbH • Edwards Lifesciences (U.S.) Inc. • Edwards Lifesciences (Japan) Limited ...
IRS number
364316614
EW stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
8 May 24
10-Q
2024 Q1
Quarterly report
29 Apr 24
8-K
Edwards Lifesciences Reports First Quarter Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Mar 24
DEFA14A
Additional proxy soliciting materials
26 Mar 24
DEFA14A
Additional proxy soliciting materials
26 Mar 24
DEF 14A
Definitive proxy
26 Mar 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
10-K
2023 FY
Annual report
12 Feb 24
8-K
Edwards Lifesciences Reports Fourth Quarter Results
6 Feb 24
Transcripts
EW
Earnings call transcript
2024 Q1
25 Apr 24
EW
Earnings call transcript
2023 Q4
6 Feb 24
EW
Earnings call transcript
2023 Q3
25 Oct 23
EW
Earnings call transcript
2023 Q2
26 Jul 23
EW
Earnings call transcript
2023 Q1
26 Apr 23
EW
Earnings call transcript
2022 Q4
31 Jan 23
EW
Earnings call transcript
2022 Q3
28 Oct 22
EW
Earnings call transcript
2022 Q2
29 Jul 22
EW
Earnings call transcript
2022 Q1
27 Apr 22
EW
Earnings call transcript
2021 Q4
27 Jan 22
Latest ownership filings
4
ROBERT W.A. SELLERS
13 May 24
4
Catherine M. Szyman
13 May 24
4
Larry L Wood
13 May 24
4
Daniel J. Lippis
13 May 24
4
Jean-Luc M Lemercier
13 May 24
4
Daveen Chopra
13 May 24
4
DONALD E BOBO JR
13 May 24
4
Bernard J Zovighian
13 May 24
4
Scott B. Ullem
13 May 24
144
Notice of proposed sale of securities
10 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.23 bn | 1.23 bn | 1.23 bn | 1.23 bn | 1.23 bn | 1.23 bn |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | (no burn) | 17.83 mm | (no burn) |
Cash used (since last report) | n/a | n/a | n/a | n/a | 28.39 mm | n/a |
Cash remaining | n/a | n/a | n/a | n/a | 1.20 bn | n/a |
Runway (months of cash) | n/a | n/a | n/a | n/a | 67.3 | n/a |
Institutional ownership, Q4 2023
55.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1002 |
Opened positions | 137 |
Closed positions | 311 |
Increased positions | 290 |
Reduced positions | 408 |
13F shares | Current |
---|---|
Total value | 23.85 tn |
Total shares | 334.77 mm |
Total puts | 471.20 k |
Total calls | 803.33 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 52.36 mm | $3.99 tn |
STT State Street | 26.96 mm | $2.06 tn |
Brown Advisory | 18.18 mm | $1.39 tn |
BK Bank Of New York Mellon | 17.33 mm | $1.32 tn |
Wellington Management | 16.83 mm | $1.28 tn |
Capital International Investors | 9.04 mm | $689.55 bn |
JPM JPMorgan Chase & Co. | 7.78 mm | $593.46 bn |
FMR | 7.50 mm | $572.03 bn |
Fisher Asset Management | 7.13 mm | $543.53 bn |
Amundi | 6.23 mm | $472.59 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 May 24 | Ullem Scott B. | Common Stock | Payment of exercise | Dispose F | No | No | 86.72 | 1,198 | 103.89 k | 30,561 |
11 May 24 | Chopra Daveen | Common Stock | Payment of exercise | Dispose F | No | No | 86.72 | 821 | 71.20 k | 30,583 |
11 May 24 | Bernard J Zovighian | Common Stock | Payment of exercise | Dispose F | No | No | 86.72 | 2,854 | 247.50 k | 76,834.901 |
11 May 24 | Sellers Robert W.a. | Common Stock | Payment of exercise | Dispose F | No | No | 86.72 | 229 | 19.86 k | 17,081.198 |
11 May 24 | Szyman Catherine M. | Common Stock | Payment of exercise | Dispose F | No | No | 86.72 | 827 | 71.72 k | 76,165.437 |
News
Here's How Much $1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today
15 May 24
Indian Rival Meril Accuses Edwards Lifesciences Of Anti-Competitive Behavior In EU Antitrust Complaint
14 May 24
Deutsche Bank Upgrades Edwards Lifesciences to Buy, Raises Price Target to $103
14 May 24
Assessing Edwards Lifesciences: Insights From 11 Financial Analysts
7 May 24
Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $101
7 May 24
Press releases
Edwards Lifesciences Reports First Quarter Results
25 Apr 24
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
18 Apr 24
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
7 Apr 24
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
11 Mar 24
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
23 Feb 24